SHERIDAN, WYOMING – November 9, 2024 – Enhancing EUV Lithography Materials Production in Japan and South Korea
In a move set to revolutionize semiconductor manufacturing, FUJIFILM Corporation has announced the launch of its cutting-edge negative-tone resists and developer for EUV lithography. This technology is poised to become the cornerstone of advanced semiconductor manufacturing processes, paving the way for smaller, more powerful chips.    

Fujifilm has earned its stripes in the industry as the pioneer behind the world's first NTI process, a negative development process that has been instrumental in miniaturizing semiconductor circuits using ArF lithography. With the introduction of its negative-tone EUV resist and EUV developer, Fujifilm continues to push the boundaries of miniaturization, optimizing circuit pattern formation for the next generation of semiconductors.    

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Holdings Corporation is pleased to announce that Kenji Sukeno, Chairman, Director & Board Chairman, has been awarded the prestigious Order of the Rising Sun, Gold and Silver Star. This distinguished honor, bestowed by the Japanese government, recognizes individuals who have made significant contributions to the nation and the public good.    
Mr. Sukeno's leadership has been instrumental in FUJIFILM's successful transformation. Despite the challenges posed by digitalization, he has guided the company to strategically invest in the healthcare sector, strengthening its foundation for future growth.    

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, vaccines, advanced therapies, and oncolytic viruses, has announced the completion of the first phase of its expansion project at its Hillerød, Denmark site.  This achievement is a significant milestone in the company's plan to establish a global network of facilities dedicated to improving the manufacturing and delivery of life-saving medications.    

The first phase of the expansion project has resulted in the addition of six mammalian cell bioreactors, increasing the total capacity at the Hillerød site to an impressive 12 x 20,000 L bioreactors.  The next phase, backed by a substantial capital investment, will see the addition of 8 x 20,000 L bioreactors and two downstream processing streams.    

SHERIDAN, WYOMING – November 9, 2024 – Company Maintains Positive Outlook for the Remainder of the Fiscal Year
FUJIFILM Holdings Corporation today announced strong financial results for the first half of the fiscal year ending March 31, 2025. The company reported a 9.1% year-over-year increase in revenue, reaching JPY1,514.7 billion. This growth was primarily fueled by strong sales in the Electronics and Imaging businesses, along with favorable foreign exchange rates.    
Operating income also demonstrated a healthy increase of 8.0% year-over-year, reaching JPY135.6 billion. The company attributed this growth to the increase in revenue and the positive impact of exchange rates.    
Despite a slight decrease in net income attributable to FUJIFILM Holdings, which was down 2.9% year-over-year to JPY110.3 billion, the company remains optimistic about its future prospects.    

SHERIDAN, WYOMING – November 9, 2024 – Varian Medical Systems, a Siemens Healthineers company, is proud to showcase its innovative TrueBeam® radiotherapy system, a cutting-edge technology designed to revolutionize cancer treatment. TrueBeam integrates hardware, software, treatment regimens, and safety features to provide clinicians with the tools they need to deliver precise and effective radiation therapy.    

"Advances in radiation therapy are accelerating, creating new options for treatment and new sources of optimism in the fight against cancer," says Varian Medical Systems.    

TrueBeam's comprehensive capabilities enable clinicians to focus on patients and treatments rather than systems and technologies. The system's integrated imaging system allows for improved soft tissue target visualization and faster cone-beam CT (CBCT) acquisitions, facilitating breath-hold treatments.

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc.

New Leadership Appointments

Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company.  Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.

Ghada Farah was appointed as Division President of the Interventional Systems Division within the Cardiac and Vascular Company. Ms. Farah brought extensive experience to this role, having previously served as Senior Vice President for EMEA in the Interventional Systems Division at Terumo Europe N.V.

SHERIDAN, WYOMING – November 9, 2024 – In a move set to transform blood processing in the United States, Terumo Blood and Cell Technologies (Terumo BCT) has launched the Reveos™ Automated Blood Processing System.  This innovative technology, already used in over 50 countries for more than a decade, promises to significantly enhance efficiency and address critical platelet shortages.

"Reveos is a revolutionary technology that automates whole blood processing. By streamlining the process, it significantly improves efficiency and consistency compared to traditional manual methods used by U.S. blood centers," says Chetan Makam, General Manager, Global Blood Solutions, Terumo BCT. "It's a new way to be more efficient for blood centers, for processing whole blood into its components including platelets. Reveos will help blood centers do more with the blood donors already walking through the doors."

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation, a leading medical technology company, has raised its financial forecast for the fiscal year ending March 31, 2025. This comes on the heels of impressive first-half results and favorable shifts in foreign exchange rates.

The company now anticipates consolidated revenue of 1.01 trillion yen, a 30 billion yen increase from its previous estimate. This upward revision reflects better-than-expected revenue in the first and second quarters, coupled with the yen's depreciation exceeding initial projections.

"Terumo's strong performance is fueled by robust growth across its various business segments, including Cardiac and Vascular, General Hospital, and Blood and Cell Technologies," said a company spokesperson. "The company's innovative products and global presence have allowed it to effectively meet the growing worldwide demand for healthcare solutions."

SHERIDAN, WYOMING – November 9, 2024 – Novartis, a global healthcare company, recently released promising data on its  Kesimpta® (ofatumumab) treatment for relapsing multiple sclerosis (RMS).  The findings, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting, highlight the long-term benefits of Kesimpta for both first-line and switch patients.

Relapsing multiple sclerosis is a chronic disease that affects the central nervous system, disrupting the flow of information within the brain, and between the brain and body.  It is characterized by periods of relapse (disease activity) and remission (recovery).  Kesimpta is a targeted B-cell therapy that works by reducing the number of B-cells, a type of immune cell thought to play a key role in MS attacks.

Kesimpta Demonstrates Sustained Efficacy in Preventing Disability Progression

SHERIDAN, WYOMING – November 9, 2024 – Novartis, a global healthcare leader, has announced exciting news from its Phase III APPLAUSE-IgAN study. Iptacopan, an investigational oral medication, has demonstrated significant potential in treating IgA nephropathy (IgAN), a rare and progressive kidney disease. This breakthrough offers renewed hope for young adults living with this challenging condition.

Understanding IgA Nephropathy

IgAN, often diagnosed in young adults, is a complex autoimmune disease where the body's immune system mistakenly attacks the kidneys. This leads to inflammation and damage, potentially resulting in kidney failure. Current treatments have limitations in addressing the root cause of the disease, highlighting the urgent need for more effective therapies.

Iptacopan: A New Approach to Treatment